Wei-Min Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei-Min Chen has a total of 501 co-authors. Here are the top co-authors by number of shared publications:
- Stephen S. Rich
University of Virginia School of Medicine
4 shared publications - Suna Onengut-Gumuscu
Department of Genome Sciences, University of Virginia School of Medicine , Charlottesville, VA
4 shared publications - Catherine C. Robertson
Gilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, USA
3 shared publications - Courtney Tern
Department of Genome Sciences, University of Virginia, Charlottesville, USA
3 shared publications - Dominika A. Michalek
Department of Genome Sciences, University of Virginia, Charlottesville, USA
3 shared publications - Adebowale Adeyemo
Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
2 shared publications
Latest Publications
- Open Access
Prediction of Polygenic Risks by Screening Thousands of Polygenic Scores
Rationale: A polygenic score (PGS) summarizes a person’s genetic information in a single number for a trait, and its utility in genomic medicine is well-recognized. Although PGS models have been generated for many traits, they are not broadly available for certain traits due to limited sample sizes in studies of infrequent outcomes. Often, prediction of these not well-studied traits ( e.g. , treatment/drug responses) would be of great clinical utility and have been underutilized due to statistical power limitations. To support more versatile trait prediction, we present a method of developing PGS models that can be used in studies of any size with genome-wide SNP data. Method: We first generate thousands of PGSs for each study participant in a given data set using their genome-wide SNP data and public resources. A PGS-wide scan involves evaluating the Area Under the Curve (AUC) of prediction for a binary trait (or the R-squared of association for a quantitative trait) at each PGS. We present two methods for the PGS model development, SECRET-Best, which selects the most predictive PGS from the PGS scan for prediction, and SECRET-WTSUM, which considers a combined score from multiple correlation-pruned PGSs. This algorithm is scalable and implemented in a user-friendly software tool, SECRET (Screen and Evaluate Catalogued Risk scores to Enhance Trait predictions). Results: We applied SECRET to a binary outcome (type 1 diabetes [T1D]) and a dataset of 2,100 samples, each with 12 laboratory test-related continuous traits. For nine traits with existing PGSs available in the PGS catalog, eight of the traits were predicted correctly, with the same trait-related PGS identified as the top predictor. We showed that the existing PGS methods had rather limited power to predict trait values in a validation set when only 1,500 samples were used to develop a PGS model, while the SECRET methods were able to maintain the prediction power for under-powered GWAS studies even when the sample size of the study was in hundreds. Conclusion: The SECRET methods and tool provide a valuable resource for studies with genomic data but of limited sample sizes. This approach enables systematic development and evaluation of PGS models.
Open AccessPrediction of Polygenic Risks by Screening Thousands of Polygenic Scores
Rationale: A polygenic score (PGS) summarizes a person’s genetic information in a single number for a trait, and its utility in genomic medicine is well-recognized. Although PGS models have been generated for many traits, they are not broadly available for certain traits due to limited sample sizes in studies of infrequent outcomes. Often, prediction of these not well-studied traits ( e.g. , treatment/drug responses) would be of great clinical utility and have been underutilized due to statistical power limitations. To support more versatile trait prediction, we present a method of developing PGS models that can be used in studies of any size with genome-wide SNP data. Method: We first generate thousands of PGSs for each study participant in a given data set using their genome-wide SNP data and public resources. A PGS-wide scan involves evaluating the Area Under the Curve (AUC) of prediction for a binary trait (or the R-squared of association for a quantitative trait) at each PGS. We present two methods for the PGS model development, SECRET-Best, which selects the most predictive PGS from the PGS scan for prediction, and SECRET-WTSUM, which considers a combined score from multiple correlation-pruned PGSs. This algorithm is scalable and implemented in a user-friendly software tool, SECRET (Screen and Evaluate Catalogued Risk scores to Enhance Trait predictions). Results: We applied SECRET to a binary outcome (type 1 diabetes [T1D]) and a dataset of 2,100 samples, each with 12 laboratory test-related continuous traits. For nine traits with existing PGSs available in the PGS catalog, eight of the traits were predicted correctly, with the same trait-related PGS identified as the top predictor. We showed that the existing PGS methods had rather limited power to predict trait values in a validation set when only 1,500 samples were used to develop a PGS model, while the SECRET methods were able to maintain the prediction power for under-powered GWAS studies even when the sample size of the study was in hundreds. Conclusion: The SECRET methods and tool provide a valuable resource for studies with genomic data but of limited sample sizes. This approach enables systematic development and evaluation of PGS models.
- Open Access
- 2 October 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (1) , 146-156
HLA-focused type 1 diabetes genetic risk prediction in populations of diverse ancestry
Aims/hypothesis: Type 1 diabetes is characterised by the destruction of pancreatic beta cells. Genetic factors account for approximately 50% of the total risk, with variants in the HLA region contributing to half of this genetic risk. Research has historically focused on populations of European ancestry. We developed HLA-focused type 1 diabetes genetic risk scores (T1D GRS HLA ) using SNPs or HLA alleles from four ancestry groups (admixed African [AFR; T1D GRS HLA-AFR ], admixed American [AMR; T1D GRS HLA-AMR ], European [EUR; T1D GRS HLA-EUR ] and Finnish [FIN; T1D GRS HLA-FIN ]). We also developed an across-ancestry GRS (ALL; T1D GRS HLA-ALL ). We assessed the performance of the GRS in each population to determine the transferability of constructed scores. Methods: A total of 41,689 samples and 13,695 SNPs in the HLA region were genotyped, with HLA alleles imputed using the HLA-TAPAS multi-ethnic reference panel. Conditionally independent SNPs and HLA alleles associated with type 1 diabetes were identified in each population group to construct T1D GRS HLA models. Generated T1D GRS HLA models were used to predict HLA-focused type 1 diabetes genetic risk across four ancestry groups. The performance of each T1D GRS HLA model was assessed using receiver operating characteristic (ROC) AUCs, and compared statistically. Results: Each T1D GRS HLA model included a different number of conditionally independent HLA-region SNPs (AFR, n =5; AMR, n =3; EUR, n =38; FIN, n =6; ALL, n =36) and HLA alleles (AFR, n =6; AMR, n =5; EUR, n =40; FIN, n =8; ALL, n =41). The ROC AUC values for the T1D GRS HLA from SNPs or HLA alleles were similar, and ranged from 0.73 (T1D GRS HLA-allele-AMR applied to FIN) to 0.88 (T1D GRS HLA-allele-EUR applied to EUR). The ROC AUC using the combined set of conditionally independent SNPs (T1D GRS HLA-SNP-ALL ) or HLA alleles (T1D GRS HLA-allele-ALL ) performed uniformly well across all ancestry groups, with values ranging from 0.82 to 0.88 for SNPs and 0.80 to 0.87 for HLA alleles. Conclusions/interpretation: T1D GRS HLA models derived from SNPs performed equivalently to those derived from HLA alleles across ancestries. In addition, T1D GRS HLA-SNP-ALL and GRS HLA-allele-ALL models had consistently high ROC AUC values when applied across ancestry groups. Larger studies in more diverse populations are needed to better assess the transferability of T1D GRS HLA across ancestries. Graphical
- 2 October 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (1) , 146-156
Open AccessHLA-focused type 1 diabetes genetic risk prediction in populations of diverse ancestry
Aims/hypothesis: Type 1 diabetes is characterised by the destruction of pancreatic beta cells. Genetic factors account for approximately 50% of the total risk, with variants in the HLA region contributing to half of this genetic risk. Research has historically focused on populations of European ancestry. We developed HLA-focused type 1 diabetes genetic risk scores (T1D GRS HLA ) using SNPs or HLA alleles from four ancestry groups (admixed African [AFR; T1D GRS HLA-AFR ], admixed American [AMR; T1D GRS HLA-AMR ], European [EUR; T1D GRS HLA-EUR ] and Finnish [FIN; T1D GRS HLA-FIN ]). We also developed an across-ancestry GRS (ALL; T1D GRS HLA-ALL ). We assessed the performance of the GRS in each population to determine the transferability of constructed scores. Methods: A total of 41,689 samples and 13,695 SNPs in the HLA region were genotyped, with HLA alleles imputed using the HLA-TAPAS multi-ethnic reference panel. Conditionally independent SNPs and HLA alleles associated with type 1 diabetes were identified in each population group to construct T1D GRS HLA models. Generated T1D GRS HLA models were used to predict HLA-focused type 1 diabetes genetic risk across four ancestry groups. The performance of each T1D GRS HLA model was assessed using receiver operating characteristic (ROC) AUCs, and compared statistically. Results: Each T1D GRS HLA model included a different number of conditionally independent HLA-region SNPs (AFR, n =5; AMR, n =3; EUR, n =38; FIN, n =6; ALL, n =36) and HLA alleles (AFR, n =6; AMR, n =5; EUR, n =40; FIN, n =8; ALL, n =41). The ROC AUC values for the T1D GRS HLA from SNPs or HLA alleles were similar, and ranged from 0.73 (T1D GRS HLA-allele-AMR applied to FIN) to 0.88 (T1D GRS HLA-allele-EUR applied to EUR). The ROC AUC using the combined set of conditionally independent SNPs (T1D GRS HLA-SNP-ALL ) or HLA alleles (T1D GRS HLA-allele-ALL ) performed uniformly well across all ancestry groups, with values ranging from 0.82 to 0.88 for SNPs and 0.80 to 0.87 for HLA alleles. Conclusions/interpretation: T1D GRS HLA models derived from SNPs performed equivalently to those derived from HLA alleles across ancestries. In addition, T1D GRS HLA-SNP-ALL and GRS HLA-allele-ALL models had consistently high ROC AUC values when applied across ancestry groups. Larger studies in more diverse populations are needed to better assess the transferability of T1D GRS HLA across ancestries. Graphical
- Open Access
HLA-focused type 1 diabetes genetic risk prediction in populations of diverse ancestry
Aims/hypothesis: Type 1 diabetes is characterized by the destruction of pancreatic beta cells. Genetic factors account for ~50% of the total risk, with variants in the Human Leukocyte Antigen (HLA) region contributing to half of this genetic risk, with research historically focused on populations of European ancestry. We developed HLA-focused type 1 diabetes genetic risk scores (T1D GRS HLA ) utilizing single nucleotide polymorphisms (SNPs) or HLA alleles from four ancestry groups (Admixed African (AFR; T1D GRS HLA-AFR ), Admixed American (AMR; T1D GRS HLA-AMR ), European (EUR; T1D GRS HLA-EUR ), Finnish (FIN; T1D GRS HLA-FIN ) and across ancestry (ALL; T1D GRS HLA-ALL ). We assessed the performance of genetic risk scores in each population to determine transferability of constructed scores. Methods: A total of 41,689 samples and 13,695 SNPs in the HLA region were genotyped, with HLA alleles imputed using the HLA TAPAS multi-ethnic reference panel. Conditionally independent SNPs and HLA alleles associated with type 1 diabetes were identified in each population group to construct T1D GRS HLA models. Generated T1D GRS HLA models were used to predict HLA-focused type 1 diabetes genetic risk across four ancestry groups. Performance of each T1D GRS HLA model was assessed using Receiver Operating Characteristic (ROC) Area Under the Curve (AUC) and compared statistically. Results: Each T1D GRS HLA model included a different number of conditionally independent HLA region SNPs (AFR, n = 5; AMR, n = 3; EUR, n = 38; FIN, n = 6; ALL, n = 36) and HLA alleles (AFR, n = 6; AMR, n = 5; EUR, n = 40; FIN, n = 8; ALL, n = 41). The ROC AUC values of T1D GRS HLA from SNPs or HLA alleles were similar and ranged from 0.73 (T1D GRS HLA-Allele-AMR applied to FIN) to 0.88 (T1D GRS HLA-Allele-EUR to EUR). The ROC AUC using the combined set of conditionally independent SNPs (T1D GRS HLA-SNP-ALL ) or HLA alleles (T1D GRS HLA-Allele-ALL ) performed uniformly well across all ancestry groups, ranging from 0.82 to 0.88 for SNPs, and 0.80 to 0.87 for HLA alleles. Conclusions/interpretation: T1D GRS HLA models derived from SNPs performed equivalently to those derived from HLA alleles across ancestries. In addition, T1D GRS HLA-SNP-ALL and GRS HLA-Allele-ALL models had consistently high ROC AUC values when applied across ancestry groups. Larger studies in more diverse populations are needed to better assess the transferability of T1D GRS HLA across ancestries.
Open AccessHLA-focused type 1 diabetes genetic risk prediction in populations of diverse ancestry
Aims/hypothesis: Type 1 diabetes is characterized by the destruction of pancreatic beta cells. Genetic factors account for ~50% of the total risk, with variants in the Human Leukocyte Antigen (HLA) region contributing to half of this genetic risk, with research historically focused on populations of European ancestry. We developed HLA-focused type 1 diabetes genetic risk scores (T1D GRS HLA ) utilizing single nucleotide polymorphisms (SNPs) or HLA alleles from four ancestry groups (Admixed African (AFR; T1D GRS HLA-AFR ), Admixed American (AMR; T1D GRS HLA-AMR ), European (EUR; T1D GRS HLA-EUR ), Finnish (FIN; T1D GRS HLA-FIN ) and across ancestry (ALL; T1D GRS HLA-ALL ). We assessed the performance of genetic risk scores in each population to determine transferability of constructed scores. Methods: A total of 41,689 samples and 13,695 SNPs in the HLA region were genotyped, with HLA alleles imputed using the HLA TAPAS multi-ethnic reference panel. Conditionally independent SNPs and HLA alleles associated with type 1 diabetes were identified in each population group to construct T1D GRS HLA models. Generated T1D GRS HLA models were used to predict HLA-focused type 1 diabetes genetic risk across four ancestry groups. Performance of each T1D GRS HLA model was assessed using Receiver Operating Characteristic (ROC) Area Under the Curve (AUC) and compared statistically. Results: Each T1D GRS HLA model included a different number of conditionally independent HLA region SNPs (AFR, n = 5; AMR, n = 3; EUR, n = 38; FIN, n = 6; ALL, n = 36) and HLA alleles (AFR, n = 6; AMR, n = 5; EUR, n = 40; FIN, n = 8; ALL, n = 41). The ROC AUC values of T1D GRS HLA from SNPs or HLA alleles were similar and ranged from 0.73 (T1D GRS HLA-Allele-AMR applied to FIN) to 0.88 (T1D GRS HLA-Allele-EUR to EUR). The ROC AUC using the combined set of conditionally independent SNPs (T1D GRS HLA-SNP-ALL ) or HLA alleles (T1D GRS HLA-Allele-ALL ) performed uniformly well across all ancestry groups, ranging from 0.82 to 0.88 for SNPs, and 0.80 to 0.87 for HLA alleles. Conclusions/interpretation: T1D GRS HLA models derived from SNPs performed equivalently to those derived from HLA alleles across ancestries. In addition, T1D GRS HLA-SNP-ALL and GRS HLA-Allele-ALL models had consistently high ROC AUC values when applied across ancestry groups. Larger studies in more diverse populations are needed to better assess the transferability of T1D GRS HLA across ancestries.
- Open Access
A multi-ancestry genome-wide association study in type 1 diabetes
Type 1 diabetes is a chronic autoimmune disease caused by destruction of the pancreatic β-cells. Genome-wide association (GWAS) and fine mapping studies associated with type 1 diabetes are mainly in European ancestry populations. We conducted a multi-ancestry GWAS to identify single nucleotide polymorphisms (SNPs) and HLA alleles associated with type 1 diabetes risk and age at onset. The Type 1 Diabetes Genetics Consortium (T1DGC) samples were genotyped using the Illumina CoreExome BeadChip array, and included families of largely European ancestry (EUR, N=3,222), unrelated individuals of African ancestry (AFR, N=891) and admixed (primarily Hispanic/Latino) ancestry (AMR, N=308). The four-digit multi-ancestry HLA reference panel (HLA-TAPAS) was used to impute HLA alleles. Logistic mixed models were used for analysis of genetic data with type 1 diabetes risk, while frailty models were used for analysis of age at onset. Seven loci were associated with type 1 diabetes at genome-wide significance (P-8 ) in the meta-analysis of the three ancestry groups: PTPN22 , HLA-DQA1 , IL2RA , RNLS , INS , IKZF4-RPS26-ERBB3 , and SH2B3 . Four loci were associated with age at onset ( PTPN22 , HLA-DQB1 , INS , and ERBB3 ). AFR and AMR meta-analysis revealed that the NRP1 locus was associated with both risk and age at onset; however, variants within NRP1 were not significantly associated with risk in those of EUR ancestry. In contrast, the PTPN22 variant rs2476601 (R620W) was significantly associated with risk only in EUR ancestry individuals. The HLA haplotype most significantly associated with risk in AFR and AMR ancestry was HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01 differed from the HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02 haplotype associated with risk in EUR ancestry. The HLA-DRB1*08:02-DQA1*04:01-DQB1*04:02 haplotype was “protective” in AMR ancestry while HLA-DRB1*08:01-DQA1*04:01-DQB1*04:02 (differing only at DRB1) was “risk” in EUR ancestry. The multi-ancestry GWAS enabled identification of ancestry-specific genetic variants, HLA alleles and haplotypes that are associated with type 1 diabetes risk and age at onset. Author Summary: Twin and family studies have shown that genetics play important role in development of type 1 diabetes in childhood. The majority of genetics studies of type 1 diabetes have been performed in populations of European ancestry. Here, we examine the influence of common genetic variants and HLA haplotypes in diverse ancestry samples of type 1 diabetes and earlier age at disease onset. We show that NRP1 region exhibits stronger association with type 1 diabetes risk and age at onset in non-European populations and PTPN22 differentiates the risk of type 1 diabetes between individuals of European and non-European ancestries. In addition, we identify protective DR-DQ HLA haplotype in Admixed individuals and DR-DQ HLA haplotype associated with increased risk for type 1 diabetes in European ancestry population. These findings could help improve identification of individuals at high genetic risk of type 1 diabetes and provide opportunities for delay or prevention of type 1 diabetes.
Open AccessA multi-ancestry genome-wide association study in type 1 diabetes
Type 1 diabetes is a chronic autoimmune disease caused by destruction of the pancreatic β-cells. Genome-wide association (GWAS) and fine mapping studies associated with type 1 diabetes are mainly in European ancestry populations. We conducted a multi-ancestry GWAS to identify single nucleotide polymorphisms (SNPs) and HLA alleles associated with type 1 diabetes risk and age at onset. The Type 1 Diabetes Genetics Consortium (T1DGC) samples were genotyped using the Illumina CoreExome BeadChip array, and included families of largely European ancestry (EUR, N=3,222), unrelated individuals of African ancestry (AFR, N=891) and admixed (primarily Hispanic/Latino) ancestry (AMR, N=308). The four-digit multi-ancestry HLA reference panel (HLA-TAPAS) was used to impute HLA alleles. Logistic mixed models were used for analysis of genetic data with type 1 diabetes risk, while frailty models were used for analysis of age at onset. Seven loci were associated with type 1 diabetes at genome-wide significance (P-8 ) in the meta-analysis of the three ancestry groups: PTPN22 , HLA-DQA1 , IL2RA , RNLS , INS , IKZF4-RPS26-ERBB3 , and SH2B3 . Four loci were associated with age at onset ( PTPN22 , HLA-DQB1 , INS , and ERBB3 ). AFR and AMR meta-analysis revealed that the NRP1 locus was associated with both risk and age at onset; however, variants within NRP1 were not significantly associated with risk in those of EUR ancestry. In contrast, the PTPN22 variant rs2476601 (R620W) was significantly associated with risk only in EUR ancestry individuals. The HLA haplotype most significantly associated with risk in AFR and AMR ancestry was HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01 differed from the HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02 haplotype associated with risk in EUR ancestry. The HLA-DRB1*08:02-DQA1*04:01-DQB1*04:02 haplotype was “protective” in AMR ancestry while HLA-DRB1*08:01-DQA1*04:01-DQB1*04:02 (differing only at DRB1) was “risk” in EUR ancestry. The multi-ancestry GWAS enabled identification of ancestry-specific genetic variants, HLA alleles and haplotypes that are associated with type 1 diabetes risk and age at onset. Author Summary: Twin and family studies have shown that genetics play important role in development of type 1 diabetes in childhood. The majority of genetics studies of type 1 diabetes have been performed in populations of European ancestry. Here, we examine the influence of common genetic variants and HLA haplotypes in diverse ancestry samples of type 1 diabetes and earlier age at disease onset. We show that NRP1 region exhibits stronger association with type 1 diabetes risk and age at onset in non-European populations and PTPN22 differentiates the risk of type 1 diabetes between individuals of European and non-European ancestries. In addition, we identify protective DR-DQ HLA haplotype in Admixed individuals and DR-DQ HLA haplotype associated with increased risk for type 1 diabetes in European ancestry population. These findings could help improve identification of individuals at high genetic risk of type 1 diabetes and provide opportunities for delay or prevention of type 1 diabetes.
- Open Access
- 21 April 2017
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 13 (4) , e1006719
Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium
Genome-wide association studies (GWAS) have identified >300 loci associated with measures of adiposity including body mass index (BMI) and waist-to-hip ratio (adjusted for BMI, WHRadjBMI), but few have been identified through screening of the African ancestry genomes. We performed large scale meta-analyses and replications in up to 52,895 individuals for BMI and up to 23,095 individuals for WHRadjBMI from the African Ancestry Anthropometry Genetics Consortium (AAAGC) using 1000 Genomes phase 1 imputed GWAS to improve coverage of both common and low frequency variants in the low linkage disequilibrium African ancestry genomes. In the sex-combined analyses, we identified one novel locus (TCF7L2/HABP2) for WHRadjBMI and eight previously established loci at P < 5×10−8: seven for BMI, and one for WHRadjBMI in African ancestry individuals. An additional novel locus (SPRYD7/DLEU2) was identified for WHRadjBMI when combined with European GWAS. In the sex-stratified analyses, we identified three novel loci for BMI (INTS10/LPL and MLC1 in men, IRX4/IRX2 in women) and four for WHRadjBMI (SSX2IP, CASC8, PDE3B and ZDHHC1/HSD11B2 in women) in individuals of African ancestry or both African and European ancestry. For four of the novel variants, the minor allele frequency was low (adjBMI loci that were locus-wide significant (P < 0.05 adjusted for effective number of variants per locus) from the African ancestry sex-combined and sex-stratified analyses, 26 BMI loci and 17 WHRadjBMI loci contained ≤ 20 variants in the credible sets that jointly account for 99% posterior probability of driving the associations. The lead variants in 13 of these loci had a high probability of being causal. As compared to our previous HapMap imputed GWAS for BMI and WHRadjBMI including up to 71,412 and 27,350 African ancestry individuals, respectively, our results suggest that 1000 Genomes imputation showed modest improvement in identifying GWAS loci including low frequency variants. Trans-ethnic meta-analyses further improved fine mapping of putative causal variants in loci shared between the African and European ancestry populations. Genome-wide association studies (GWAS) have identified >300 genetic regions that influence body size and shape as measured by body mass index (BMI) and waist-to-hip ratio (WHR), respectively, but few have been identified in populations of African ancestry. We conducted large scale high coverage GWAS and replication of these traits in 52,895 and 23,095 individuals of African ancestry, respectively, followed by additional replication in European populations. We identified 10 genome-wide significant loci in all individuals, and an additional seven loci by analyzing men and women separately. We combined African and European ancestry GWAS and were able to narrow down 43 out of 74 African ancestry associated genetic regions to contain small number of putative causal variants. Our results highlight the improvement of applying high density genome coverage and combining multiple ancestries in the identification and refinement of location of genetic regions associated with adiposity traits.
- 21 April 2017
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 13 (4) , e1006719
Open AccessDiscovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium
Genome-wide association studies (GWAS) have identified >300 loci associated with measures of adiposity including body mass index (BMI) and waist-to-hip ratio (adjusted for BMI, WHRadjBMI), but few have been identified through screening of the African ancestry genomes. We performed large scale meta-analyses and replications in up to 52,895 individuals for BMI and up to 23,095 individuals for WHRadjBMI from the African Ancestry Anthropometry Genetics Consortium (AAAGC) using 1000 Genomes phase 1 imputed GWAS to improve coverage of both common and low frequency variants in the low linkage disequilibrium African ancestry genomes. In the sex-combined analyses, we identified one novel locus (TCF7L2/HABP2) for WHRadjBMI and eight previously established loci at P < 5×10−8: seven for BMI, and one for WHRadjBMI in African ancestry individuals. An additional novel locus (SPRYD7/DLEU2) was identified for WHRadjBMI when combined with European GWAS. In the sex-stratified analyses, we identified three novel loci for BMI (INTS10/LPL and MLC1 in men, IRX4/IRX2 in women) and four for WHRadjBMI (SSX2IP, CASC8, PDE3B and ZDHHC1/HSD11B2 in women) in individuals of African ancestry or both African and European ancestry. For four of the novel variants, the minor allele frequency was low (adjBMI loci that were locus-wide significant (P < 0.05 adjusted for effective number of variants per locus) from the African ancestry sex-combined and sex-stratified analyses, 26 BMI loci and 17 WHRadjBMI loci contained ≤ 20 variants in the credible sets that jointly account for 99% posterior probability of driving the associations. The lead variants in 13 of these loci had a high probability of being causal. As compared to our previous HapMap imputed GWAS for BMI and WHRadjBMI including up to 71,412 and 27,350 African ancestry individuals, respectively, our results suggest that 1000 Genomes imputation showed modest improvement in identifying GWAS loci including low frequency variants. Trans-ethnic meta-analyses further improved fine mapping of putative causal variants in loci shared between the African and European ancestry populations. Genome-wide association studies (GWAS) have identified >300 genetic regions that influence body size and shape as measured by body mass index (BMI) and waist-to-hip ratio (WHR), respectively, but few have been identified in populations of African ancestry. We conducted large scale high coverage GWAS and replication of these traits in 52,895 and 23,095 individuals of African ancestry, respectively, followed by additional replication in European populations. We identified 10 genome-wide significant loci in all individuals, and an additional seven loci by analyzing men and women separately. We combined African and European ancestry GWAS and were able to narrow down 43 out of 74 African ancestry associated genetic regions to contain small number of putative causal variants. Our results highlight the improvement of applying high density genome coverage and combining multiple ancestries in the identification and refinement of location of genetic regions associated with adiposity traits.
- Open Access
- 16 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 27887
Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study
A total of 15 SNPs within complement genes and present on the ImmunoChip were analyzed in The Environmental Determinants of Diabetes in the Young (TEDDY) study. A total of 5474 subjects were followed from three months of age until islet autoimmunity (IA: n = 413) and the subsequent onset of type 1 diabetes (n = 115) for a median of 73 months (IQR 54–91). Three SNPs within ITGAM were nominally associated (p < 0.05) with IA: rs1143678 [Hazard ratio; HR 0.80; 95% CI 0.66–0.98; p = 0.032], rs1143683 [HR 0.80; 95% CI 0.65–0.98; p = 0.030] and rs4597342 [HR 1.16; 95% CI 1.01–1.32; p = 0.041]. When type 1 diabetes was the outcome, in DR3/4 subjects, there was nominal significance for two SNPs: rs17615 in CD21 [HR 1.52; 95% CI 1.05–2.20; p = 0.025] and rs4844573 in C4BPA [HR 0.63; 95% CI 0.43–0.92; p = 0.017]. Among DR4/4 subjects, rs2230199 in C3 was significantly associated [HR 3.20; 95% CI 1.75–5.85; p = 0.0002, uncorrected] a significance that withstood Bonferroni correction since it was less than 0.000833 (0.05/60) in the HLA-specific analyses. SNPs within the complement genes may contribute to IA, the first step to type 1 diabetes, with at least one SNP in C3 significantly associated with clinically diagnosed type 1 diabetes.
- 16 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 27887
Open AccessComplement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study
A total of 15 SNPs within complement genes and present on the ImmunoChip were analyzed in The Environmental Determinants of Diabetes in the Young (TEDDY) study. A total of 5474 subjects were followed from three months of age until islet autoimmunity (IA: n = 413) and the subsequent onset of type 1 diabetes (n = 115) for a median of 73 months (IQR 54–91). Three SNPs within ITGAM were nominally associated (p < 0.05) with IA: rs1143678 [Hazard ratio; HR 0.80; 95% CI 0.66–0.98; p = 0.032], rs1143683 [HR 0.80; 95% CI 0.65–0.98; p = 0.030] and rs4597342 [HR 1.16; 95% CI 1.01–1.32; p = 0.041]. When type 1 diabetes was the outcome, in DR3/4 subjects, there was nominal significance for two SNPs: rs17615 in CD21 [HR 1.52; 95% CI 1.05–2.20; p = 0.025] and rs4844573 in C4BPA [HR 0.63; 95% CI 0.43–0.92; p = 0.017]. Among DR4/4 subjects, rs2230199 in C3 was significantly associated [HR 3.20; 95% CI 1.75–5.85; p = 0.0002, uncorrected] a significance that withstood Bonferroni correction since it was less than 0.000833 (0.05/60) in the HLA-specific analyses. SNPs within the complement genes may contribute to IA, the first step to type 1 diabetes, with at least one SNP in C3 significantly associated with clinically diagnosed type 1 diabetes.
- Open Access
- 16 May 2016
- Published by Springer Nature in Nature Genetics
- Vol. 48 (7) , 803-810
A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases
Soumya Raychaudhuri, Buhm Han and colleagues present a statistical method to distinguish whether shared genetic risk variants among complex traits are driven by whole-group pleiotropy or a subset of individuals who constitute a genetically heterogeneous subgroup. They use the method to examine genetic sharing among autoimmune diseases and between major depressive disorder and schizophrenia and find that most genetic sharing cannot be explained by subgroup heterogeneity but that, in contrast, seronegative rheumatoid arthritis is a heterogeneous condition. There is growing evidence of shared risk alleles for complex traits (pleiotropy), including autoimmune and neuropsychiatric diseases. This might be due to sharing among all individuals (whole-group pleiotropy) or a subset of individuals in a genetically heterogeneous cohort (subgroup heterogeneity). Here we describe the use of a well-powered statistic, BUHMBOX, to distinguish between those two situations using genotype data. We observed a shared genetic basis for 11 autoimmune diseases and type 1 diabetes (T1D; P < 1 × 10−4) and for 11 autoimmune diseases and rheumatoid arthritis (RA; P < 1 × 10−3). This sharing was not explained by subgroup heterogeneity (corrected PBUHMBOX > 0.2; 6,670 T1D cases and 7,279 RA cases). Genetic sharing between seronegative and seropostive RA (P < 1 × 10−9) had significant evidence of subgroup heterogeneity, suggesting a subgroup of seropositive-like cases within seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative RA cases). We also observed a shared genetic basis for major depressive disorder (MDD) and schizophrenia (P < 1 × 10−4) that was not explained by subgroup heterogeneity (PBUHMBOX = 0.28; 9,238 MDD cases).
- 16 May 2016
- Published by Springer Nature in Nature Genetics
- Vol. 48 (7) , 803-810
Open AccessA method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases
Soumya Raychaudhuri, Buhm Han and colleagues present a statistical method to distinguish whether shared genetic risk variants among complex traits are driven by whole-group pleiotropy or a subset of individuals who constitute a genetically heterogeneous subgroup. They use the method to examine genetic sharing among autoimmune diseases and between major depressive disorder and schizophrenia and find that most genetic sharing cannot be explained by subgroup heterogeneity but that, in contrast, seronegative rheumatoid arthritis is a heterogeneous condition. There is growing evidence of shared risk alleles for complex traits (pleiotropy), including autoimmune and neuropsychiatric diseases. This might be due to sharing among all individuals (whole-group pleiotropy) or a subset of individuals in a genetically heterogeneous cohort (subgroup heterogeneity). Here we describe the use of a well-powered statistic, BUHMBOX, to distinguish between those two situations using genotype data. We observed a shared genetic basis for 11 autoimmune diseases and type 1 diabetes (T1D; P < 1 × 10−4) and for 11 autoimmune diseases and rheumatoid arthritis (RA; P < 1 × 10−3). This sharing was not explained by subgroup heterogeneity (corrected PBUHMBOX > 0.2; 6,670 T1D cases and 7,279 RA cases). Genetic sharing between seronegative and seropostive RA (P < 1 × 10−9) had significant evidence of subgroup heterogeneity, suggesting a subgroup of seropositive-like cases within seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative RA cases). We also observed a shared genetic basis for major depressive disorder (MDD) and schizophrenia (P < 1 × 10−4) that was not explained by subgroup heterogeneity (PBUHMBOX = 0.28; 9,238 MDD cases).
- 29 March 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (13) , 1217-1226
Low-frequency and common genetic variation in ischemic stroke
Objective: To investigate the influence of common and low-frequency genetic variants on the risk of ischemic stroke (all IS) and etiologic stroke subtypes. Methods: We meta-analyzed 12 individual genome-wide association studies comprising 10,307 cases and 19,326 controls imputed to the 1000 Genomes (1 KG) phase I reference panel. We selected variants showing the highest degree of association (p < 1E-5) in the discovery phase for replication in Caucasian (13,435 cases and 29,269 controls) and South Asian (2,385 cases and 5,193 controls) samples followed by a transethnic meta-analysis. We further investigated the p value distribution for different bins of allele frequencies for all IS and stroke subtypes. Results: We showed genome-wide significance for 4 loci: ABO for all IS, HDAC9 for large vessel disease (LVD), and both PITX2 and ZFHX3 for cardioembolic stroke (CE). We further refined the association peaks for ABO and PITX2. Analyzing different allele frequency bins, we showed significant enrichment in low-frequency variants (allele frequency p < 1E-5). Conclusions: Our findings suggest that the missing heritability in IS subtypes can in part be attributed to low-frequency and rare variants. Larger sample sizes are needed to identify the variants associated with all IS and stroke subtypes.
- 29 March 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (13) , 1217-1226
Low-frequency and common genetic variation in ischemic stroke
Objective: To investigate the influence of common and low-frequency genetic variants on the risk of ischemic stroke (all IS) and etiologic stroke subtypes. Methods: We meta-analyzed 12 individual genome-wide association studies comprising 10,307 cases and 19,326 controls imputed to the 1000 Genomes (1 KG) phase I reference panel. We selected variants showing the highest degree of association (p < 1E-5) in the discovery phase for replication in Caucasian (13,435 cases and 29,269 controls) and South Asian (2,385 cases and 5,193 controls) samples followed by a transethnic meta-analysis. We further investigated the p value distribution for different bins of allele frequencies for all IS and stroke subtypes. Results: We showed genome-wide significance for 4 loci: ABO for all IS, HDAC9 for large vessel disease (LVD), and both PITX2 and ZFHX3 for cardioembolic stroke (CE). We further refined the association peaks for ABO and PITX2. Analyzing different allele frequency bins, we showed significant enrichment in low-frequency variants (allele frequency p < 1E-5). Conclusions: Our findings suggest that the missing heritability in IS subtypes can in part be attributed to low-frequency and rare variants. Larger sample sizes are needed to identify the variants associated with all IS and stroke subtypes.
- Open Access
A pan-cancer analysis of prognostic genes
Numerous studies have identified prognostic genes in individual cancers, but a thorough pan-cancer analysis has not been performed. In addition, previous studies have mostly used microarray data instead of RNA-SEQ, and have not published comprehensive lists of associations with survival. Using recently available RNA-SEQ and clinical data from The Cancer Genome Atlas for 6,495 patients, we have investigated every annotated and expressed gene’s association with survival across 16 cancer types. The most statistically significant harmful and protective genes were not shared across cancers, but were enriched in distinct gene sets which were shared across certain groups of cancers. These groups of cancers were independently recapitulated by both unsupervised clustering of Cox coefficients (a measure of association with survival) for individual genes, and for gene programs. This analysis has revealed unappreciated commonalities among cancers which may provide insights into cancer pathogenesis and rationales for co-opting treatments between cancers.
Open AccessA pan-cancer analysis of prognostic genes
Numerous studies have identified prognostic genes in individual cancers, but a thorough pan-cancer analysis has not been performed. In addition, previous studies have mostly used microarray data instead of RNA-SEQ, and have not published comprehensive lists of associations with survival. Using recently available RNA-SEQ and clinical data from The Cancer Genome Atlas for 6,495 patients, we have investigated every annotated and expressed gene’s association with survival across 16 cancer types. The most statistically significant harmful and protective genes were not shared across cancers, but were enriched in distinct gene sets which were shared across certain groups of cancers. These groups of cancers were independently recapitulated by both unsupervised clustering of Cox coefficients (a measure of association with survival) for individual genes, and for gene programs. This analysis has revealed unappreciated commonalities among cancers which may provide insights into cancer pathogenesis and rationales for co-opting treatments between cancers.
- 26 January 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (4) , 351-359
Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke
Objective: To investigate the genetic contributors to cerebrovascular disease and variation in biomarkers of ischemic stroke. Methods: The Vitamin Intervention for Stroke Prevention Trial (VISP) was a randomized, controlled clinical trial of B vitamin supplementation to prevent recurrent stroke, myocardial infarction, or death. VISP collected baseline measures of C-reactive protein (CRP), fibrinogen, creatinine, prothrombin fragments F1+2, thrombin-antithrombin complex, and thrombomodulin prior to treatment initiation. Genome-wide association scans were conducted for these traits and follow-up replication analyses were performed. Results: We detected an association between CRP single nucleotide polymorphisms (SNPs) and circulating CRP levels (most associated SNP, rs2592902, p = 1.14 × 10−9) in 2,100 VISP participants. We discovered a novel association for CRP level in the AKR1D1 locus (rs2589998, p = 7.3 × 10−8, approaching genome-wide significance) that also is an expression quantitative trait locus for CRP gene expression. We replicated previously identified associations of fibrinogen with SNPs in the FGB and LEPR loci. CRP-associated SNPs and CRP levels were significantly associated with risk of ischemic stroke and recurrent stroke in VISP as well as specific stroke subtypes in METASTROKE. Fibrinogen levels but not fibrinogen-associated SNPs were also found to be associated with recurrent stroke in VISP. Conclusions: Our data identify a genetic contribution to inflammatory and hemostatic biomarkers in a stroke population. Additionally, our results suggest shared genetic contributions to circulating CRP levels measured poststroke and risk for incident and recurrent ischemic stroke. These data broaden our understanding of genetic contributors to biomarker variation and ischemic stroke risk, which should be useful in clinical risk evaluation.
- 26 January 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (4) , 351-359
Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke
Objective: To investigate the genetic contributors to cerebrovascular disease and variation in biomarkers of ischemic stroke. Methods: The Vitamin Intervention for Stroke Prevention Trial (VISP) was a randomized, controlled clinical trial of B vitamin supplementation to prevent recurrent stroke, myocardial infarction, or death. VISP collected baseline measures of C-reactive protein (CRP), fibrinogen, creatinine, prothrombin fragments F1+2, thrombin-antithrombin complex, and thrombomodulin prior to treatment initiation. Genome-wide association scans were conducted for these traits and follow-up replication analyses were performed. Results: We detected an association between CRP single nucleotide polymorphisms (SNPs) and circulating CRP levels (most associated SNP, rs2592902, p = 1.14 × 10−9) in 2,100 VISP participants. We discovered a novel association for CRP level in the AKR1D1 locus (rs2589998, p = 7.3 × 10−8, approaching genome-wide significance) that also is an expression quantitative trait locus for CRP gene expression. We replicated previously identified associations of fibrinogen with SNPs in the FGB and LEPR loci. CRP-associated SNPs and CRP levels were significantly associated with risk of ischemic stroke and recurrent stroke in VISP as well as specific stroke subtypes in METASTROKE. Fibrinogen levels but not fibrinogen-associated SNPs were also found to be associated with recurrent stroke in VISP. Conclusions: Our data identify a genetic contribution to inflammatory and hemostatic biomarkers in a stroke population. Additionally, our results suggest shared genetic contributions to circulating CRP levels measured poststroke and risk for incident and recurrent ischemic stroke. These data broaden our understanding of genetic contributors to biomarker variation and ischemic stroke risk, which should be useful in clinical risk evaluation.